<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2575">
  <stage>Registered</stage>
  <submitdate>16/11/2009</submitdate>
  <approvaldate>16/11/2009</approvaldate>
  <nctid>NCT01014975</nctid>
  <trial_identification>
    <studytitle>A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients</studytitle>
    <scientifictitle>A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-019760-36</secondaryid>
    <secondaryid>T05018-1001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Ischemic Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Plasmin (Human)
Other interventions - Plasmin (Human)
Other interventions - Plasmin (Human)

Experimental: 20 mg Plasmin (Human) - 20 mg of Plasmin (Human)

Experimental: 40 mg Plasmin (Human) - 40 mg of Plasmin (Human)

Experimental: 80 mg Plasmin (Human) - 80 mg of Plasmin (Human)


Other interventions: Plasmin (Human)
Plasmin (Human), 20 mg, delivered through a catheter into a thrombus

Other interventions: Plasmin (Human)
Plasmin (Human), 40 mg, delivered through a catheter into a thrombus

Other interventions: Plasmin (Human)
Plasmin (Human), 80 mg, delivered through a catheter into a thrombus

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Symptomatic Intracranial Hemorrhage (SICH) by Dose Cohort</outcome>
      <timepoint>90 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. 18 to 85 years of age

          2. Male or female

          3. New focal, potentially disabling neurologic deficit clinically localized to the MCA
             distribution

          4. Intra-arterial therapy with Plasmin completed within 9 hours of stroke onset

          5. A National Institutes of Health Stroke Scale score = 4 and = 25</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Intracranial procedures or intracranial or systemic bleeding within the last year

          2. Intracranial neoplasm (except meningioma), septic embolism, or unsecured aneurysm

          3. Active bleeding

          4. History of stroke in previous 6 weeks

          5. Uncontrolled hypertension

          6. Renal disease or renal dialysis

          7. Treatment with any plasminogen activator within the last 48 hrs.

          8. Therapy with a Glycoprotein IIb/IIIa inhibitor in 5 days prior to study enrollment or
             at any time during study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Heidelberg Repatriation Hospital, Melbourne - Heidelberg</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Upper Austria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Kragujevac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Niš</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Sad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Banská Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Martin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Ružomberok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Grifols Therapeutics Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the
      middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot
      component, fibrin. In this study, Plasmin (Human) is administered locally through a catheter
      to the clot within 9 hours of the stroke onset. Three doses of Plasmin (Human) (20 mg, 40 mg,
      and 80 mg) are being tested in 3 different groups of patients. Patients are monitored by
      imaging of the affected artery and functional testing.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01014975</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jeffrey Saver, MD</name>
      <address>University of California, Los Angeles</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>